-
Love, lust and gnomes as top UK flower show bursts into bloom
-
Fans of historic DC park wary of Trump plan to 'beautify' city
-
As bee population collapses, US apiarists fear research cuts
-
Lights out for Cuban students as blockade bites
-
Campaigners warn Italy's gutted rape bill could help assailants
-
Libyan ex-prison boss faces ICC war crimes hearing
-
Argentine scientists lay first traps in hantavirus hunt
-
Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'
-
Harry Styles fans to splash over £1 bn on London concerts: Barclays
-
Bolivia protest sees violent clashes, looting in La Paz
-
Trump says held off on new Iran attack, upbeat for agreement
-
Los Angeles World Cup workers vow strike over ICE guarantees
-
Three killed in San Diego mosque shooting, two attackers dead
-
US to screen for Ebola at airports, one American in DR Congo infected
-
Aussie Scott officially set for 100th straight major at US Open
-
Pep Guardiola to leave Man City at end of the season - reports
-
Neymar back in Brazil squad for fourth World Cup
-
Arsenal on the brink of Premier League title after nervy Burnley win
-
Oil rises, global stocks mixed as markets track Iran developments
-
World Cup winner Pavard confirms Marseille exit
-
Trump says holding off on new Iran attack
-
Cuba warns of 'bloodbath' if US attacks; Washington adds sanctions
-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
-
Andalusia setback highlights weakness of Spain's ruling Socialists
-
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
-
Middle East tourism pain is Europe's gain
-
UK Labour leadership hopeful reopens Brexit debate
-
PSG's Dembele has treatment for leg issue before Champions League final
-
Spurs must play with 'courage' to seal safety: De Zerbi
-
Hantavirus-hit cruise ship ends deadly voyage
-
Champagne start in Reims for 2028 Tour de France
-
Dogs allowed on new Brigitte Bardot beach in glitzy Cannes
-
Oil prices dip on report of US sanctions relief for Iran during talks
-
Croatia names Modric-led World Cup squad
-
Iran World Cup squad lands in south Turkey for training
-
Mushfiqur ton leaves Pakistan needing record run chase to beat Bangladesh
-
Transport protests hit Kenya over rising fuel prices
-
Ex-Google exec takes reins at under-fire BBC
Research on multiple sclerosis wins 'Oscars of science'
An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on Saturday won a prestigious Breakthrough Prize, the award nicknamed the "Oscars of science."
Stephen Hauser and Alberto Ascherio were recognized for their decades researching the debilitating neurodegenerative disease, which affects nearly three million people worldwide and was long considered an impenetrable enigma.
Hauser's work on multiple sclerosis (MS) started more than 45 years ago, when he met a young patient named Andrea, "an extraordinarily talented young woman who was already an attorney" and working at the White House under then-president Jimmy Carter, he told AFP.
"Then MS appeared in an explosive fashion and destroyed her life," he said.
"I remember seeing her, unable to speak, paralyzed on the right side, unable to swallow, and soon, unable to breathe on her own, and I remember thinking that this was the most unfair thing I had ever seen in medicine."
Then 27 years old, he decided to make it his life's work.
- Rough road -
"At the time, we had no treatments for MS. In fact, there was also a pessimism that treatments could ever be developed," said Hauser, now 74 and director of the neuroscience institute at the University of California San Francisco.
Scientists knew the disease, which damages the central nervous system and leads to paralyzing cognitive and motor problems, was caused by the immune system turning on the body.
But they thought the white blood cells known as T cells were the lone culprit.
Hauser questioned that.
Studying the role played in the disease by B cells, another type of white blood cell, he and his colleagues managed to recreate the damage MS causes to the human nervous system in small monkeys known as marmosets.
The US federal body overseeing medical research dismissed the link as "biologically implausible," and turned down their application for funding for a clinical trial.
But Hauser and his team pressed on.
They persuaded pharmaceutical company Genentech to back testing. In 2006, they got resounding results: treatments targeting B cells were associated with "a dramatic, more than 90-percent reduction in brain inflammation," Hauser said.
It was "something of a scope that had never been seen before."
That threw open a door to bring new treatments to market that slow the advance of the disease in many patients.
But it also raised other questions. For example, what would cause our white blood cells to turn against us?
- The virus connection -
That was a question that puzzled Ascherio, today a professor at Harvard.
He decided to investigate why MS mostly affected people in the northern hemisphere.
"The geographical distribution of MS was quite striking," he told AFP.
"MS is very uncommon in tropical countries and near the equator."
That made him wonder whether a virus could be involved.
He and his team carried out a long-term study following millions of young US military recruits.
After nearly 20 years of research, they came up with an answer. In 2022, they confirmed a link between MS and the Epstein-Barr virus (EBV), a common infection responsible for another well-known disease, infectious mononucleosis, or mono.
"Most people infected with EBV will never develop MS," said Ascherio, 72.
But everyone who develops MS has had EBV first.
The discovery still did not explain why MS occurs. But it fuelled hope of finding new treatments and preventive measures for a disease that remains uncurable, and whose current treatments do not work on all patients.
Ascherio's breakthrough could also help treat other conditions.
"We are now trying also to extend our investigation, to investigate the role of viral infection in other neurodegenerative diseases, like Alzheimer's or amyotrophic lateral sclerosis," also known as ALS or Lou Gehrig's disease, he said.
The link remains theoretical for now. But "there is some evidence," he said.
"It's like where we were on MS 20 or 30 years ago."
A.AbuSaada--SF-PST